Trials / Recruiting
RecruitingNCT07036029
NAL ER IPF Respiratory Function and Safety Study
An Open Label, In-Clinic Study to Assess Respiratory Function and Safety of Escalating Doses of Nalbuphine Extended-Release Tablets (NAL ER) in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- Trevi Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study is to assess the safety and tolerability of escalating doses of NAL ER and to evaluate its effect on respiratory function in participants with IPF.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NAL ER | Oral tablets |
| DRUG | Placebo | Oral tablets |
Timeline
- Start date
- 2025-08-21
- Primary completion
- 2026-06-30
- Completion
- 2026-06-30
- First posted
- 2025-06-25
- Last updated
- 2026-04-09
Locations
2 sites across 2 countries: United States, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07036029. Inclusion in this directory is not an endorsement.